Interferon beta-1b is a form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms. Human interferon beta (165 residues), cysteine 17 is substituted with serine.
- Mechanism
- Curator reviewed
Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.
- Primary indication
- Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis.Curator reviewed · 2 structured indications
- Formula / weight
- C908H1408N246O253S6 · 20011.0 Da
- First approval
- Canada, 2007 · United States, 2009 · European Union, 2016
- Also known as
- Interferon beta 1b (recombinant) · Interferon beta-1b,recombinant · Interferon-beta-1b · Recombinant interferon beta-1b
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Interferon beta-1b, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account